SecBot SecBot
8-K ·Filed Aug 31, 2026

KPTI

Karyopharm Therapeutics Inc.
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago SEC0001193125-26-375495
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Monitor FDA acceptance decision in Q4 2026, if the sNDA is accepted with Priority Review, the target action date would be approximately six months later. Approval would open a new indication for XPOVIO, but the binary risk of non-acceptance or FDA disagreement on the surrogate endpoint remains high given the company's $42M market cap and going concern warning.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$2.06
T+0 close · Aug 31, 2026 · via day close
Latest settled
−41.50%
T+20 · $1.21 · next T+60 in 7d
Vs SPY
−41.32%
α at T+20
Latest observation
−59.58%
T+30 · FF3 residual α
  1. T+0 · Aug 31 $2.06entry
  2. T+1 · 3mo ago −10.19%α −9.51% · $1.85
  3. T+5 · 2mo ago −16.50%α −16.36% · $1.72
  4. T+20 · 7w ago −41.50%α −41.32% · $1.21
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis, based on Phase 3 SENTRY trial data showing a promising overall survival signal. Priority Review was requested, which could yield a six-month review cycle. FDA acceptance and review timeline decisions are expected in Q4 2026.

Key Facts

  • sNDA submitted for XPOVIO (selinexor) + ruxolitinib in myelofibrosis under Accelerated Approval pathway
  • Priority Review requested; if granted, review period would be approximately six months
  • FDA decision on sNDA filing acceptance and review timelines expected in Q4 2026
  • Submission based on Phase 3 SENTRY trial data with a positive benefit-risk profile and overall survival signal
  • Accelerated Approval requires FDA agreement that SVR35 is a reasonably likely surrogate endpoint for overall survival
  • Company plans to use long-term overall survival data from SENTRY to support conversion to traditional approval

Financial Impact

No specific financial figures provided; potential expansion of XPOVIO addressable market into myelofibrosis if approved. Company has going concern risk noted in forward-looking statements.

revenue

Risk Factors

  • FDA may not accept the sNDA or may deny Priority Review
  • FDA may not agree that SVR35 is a reasonably likely surrogate endpoint for overall survival
  • Company has expressed substantial doubt about its ability to continue as a going concern
  • Long-term overall survival data from SENTRY may not verify clinical benefit, preventing conversion to traditional approval

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-375495
Document: 0001193125-26-375495-index-headers.html0001193125-26-375495
Document: 0001193125-26-375495-index.html0001193125-26-375495
Document: 0001193125-26-375495.txt0001193125-26-375495

US Market Status

Market Closed · Opens in 8h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026